openPR Logo
Press release

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Key Players Analysis - Axol Bioscience Ltd, DefiniGEN, REPROCELL, The Jackson Laboratory, Creative Biolabs.

12-06-2024 07:55 AM CET | Health & Medicine

Press release from: InsightAce Analytic Pvt. Ltd

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market- (Disease (Neurological Disorders and Dystrophies, Cardiac disorders, Retinal Eye Disease, Metabolic Disorders, Liver disease, Others), Products and Services (Disease Model, Reprogramming service, Differentiation service, Screening service, Characterization service, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market is expected to grow with a CAGR of 11.2% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2556

Human-induced pluripotent stem cells (hiPSCs) have revolutionized preclinical disease modeling and drug development by offering a robust platform derived from reprogrammed adult somatic cells, such as skin or blood cells, to an embryonic-like pluripotent state. This transformation enables hiPSCs to differentiate into diverse cell types, including those impacted by diseases, thereby providing unprecedented opportunities to investigate disease mechanisms and evaluate potential therapies. The versatility of hiPSCs in modeling various diseases has fueled substantial growth in the hiPSCs preclinical disease model market.

In addition to disease-specific modeling, hiPSCs empower researchers to employ gene editing technologies to correct disease-causing mutations within these cells. This approach not only elucidates the impact of genetic variations on disease development but also supports the development of potential gene therapies. Moreover, hiPSCs are pivotal in constructing complex, multi-lineage tissue models that closely mimic physiological conditions in vivo. These advanced tissue models offer a more accurate platform for testing drug efficacy and safety before clinical trials, thereby advancing the prospects of personalized medicine. Collectively, the hiPSCs preclinical disease model market continues to expand driven by its unparalleled ability to replicate disease states, study molecular mechanisms, and accelerate the discovery of novel therapeutic interventions.

List of Prominent Players in the Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market:
• Axol Bioscience Ltd
• DefiniGEN
• REPROCELL
• The Jackson Laboratory
• Creative Biolabs
• Cyagen
• FUJIFILM Cellular Dynamics
• ElevateBio
• Bio-Techne
• BPS Bioscience, Inc.
• Catalent, Inc
• Ncardia
• NEXEL Co
• Evotec's
• iXCells Biotechnologies
• Elixirgen
• Other Prominent Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:
Drivers:
Human-induced pluripotent stem cells (hiPSCs) are pivotal driving forces in the growth of the preclinical disease model market due to their exceptional versatility in modeling a diverse range of diseases. These cells are adept at representing conditions such as neurological disorders (e.g., Parkinson's, Alzheimer's, Huntington's, ALS), cardiac disorders, metabolic disorders, liver disease, and more, making them invaluable tools across various therapeutic areas in biomedical research and drug development. In neurological disorders specifically, hiPSC-based models have demonstrated significant success in generating disease-specific cell lines and studying affected cell types, thereby addressing critical gaps in understanding disease mechanisms. Additionally, hiPSC-based models are increasingly preferred over animal models in preclinical trials due to their potential to provide more predictive insights into human physiology and meet regulatory standards for drug testing. Advances in tissue engineering techniques, such as 3D organoids and organ-on-a-chip systems utilizing hiPSCs, further enhance their utility by better replicating in vivo physiology and disease pathophysiology, driving further adoption in the hiPSCs preclinical disease model market towards more effective therapeutic development and personalized medicine strategies.

Challenges:
Despite their significant advantages, human-induced pluripotent stem cell (hiPSC)-derived models face notable challenges that limit their predictivity in disease modeling and drug development. One critical issue is the physiological immaturity of hiPSC-derived cells, such as cardiomyocytes (hiPSC-CMs), compared to adult cells, which can affect their ability to accurately replicate disease phenotypes and drug responses. Another limitation is the architectural simplicity of current culture systems used for hiPSC-derived cells, which may not fully capture the complexity of in vivo physiology, further impacting the fidelity of disease mechanisms and drug effects in these models. Moreover, while efforts to implement complex 3D tissue engineering solutions aim to enhance physiological relevance, scaling these approaches for high-throughput screening remains challenging.

Regional Trends:
The human-induced pluripotent stem cells (hiPSCs) preclinical disease model market is witnessing substantial growth in North America, driven by several key factors. Firstly, the region boasts a robust pharmaceutical and biotechnology ecosystem, particularly in the United States, where major industry players and research institutions are actively adopting hiPSC-based technologies for advancing preclinical drug development. Secondly, North America benefits from a supportive regulatory environment led by agencies like the U.S. Food and Drug Administration (FDA), which encourages the validation and utilization of hiPSC-derived models in research and development.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2556

Recent Developments:
• In May 2024, REPROCELL is now offering Master Cell Bank (MCB) manufacturing services for Human Induced Pluripotent Stem Cells (hiPSCs) and Human Mesenchymal Stem Cells (hMSCs) tailored for human therapeutic applications. Our process includes stringent control from donor recruitment to seed stock hiPSC production, ensuring compliance with regulatory agencies across various geographical regions.
• In August 2022, ElevateBio, LLC collaborated with George Daley, M.D., Ph.D., and Boston Children's Hospital to launch a new company. This initiative aims to develop allogeneic immune cell therapies using a novel platform that produces mature immune cells from induced pluripotent stem cells (iPSCs). This innovative approach addresses the challenge of iPSCs typically generating immature embryonic blood cell types, ensuring the creation of diverse immune cell subtypes with mature molecular characteristics similar to adult T cells derived from blood.

Segmentation of Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market-
By Disease
• Neurological Disorders and Dystrophies
• Cardiac Disorders
• Retinal Eye Disease
• Metabolic Disorders
• Liver Disease
• Others
By Products and Services
• Disease Model
• Reprogramming Service
• Differentiation Service
• Screening Service
• Characterization Service
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2556

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Key Players Analysis - Axol Bioscience Ltd, DefiniGEN, REPROCELL, The Jackson Laboratory, Creative Biolabs. here

News-ID: 3775246 • Views:

More Releases from InsightAce Analytic Pvt. Ltd

Air Freight market Key Players Analysis - DSV Panalpina, Expeditors International of Washington, Inc., FedEx, Hellmann Worldwide Logistics.
Air Freight market Key Players Analysis - DSV Panalpina, Expeditors Internationa …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Air Freight Market Size, Share & Trends Analysis Report By Service (Freight, Express, Mail, and Other Services), Destination (Domestic and International), and End-Use (Private and Commercial)- Market Outlook And Industry Analysis 2031" The global Air Freight market is estimated to reach over USD 483.28 billion by 2031, exhibiting a CAGR of 6.17% during the forecast period.
ESG Reporting Software Market Detailed Analysis with Accurate Forecast to 2031
ESG Reporting Software Market Detailed Analysis with Accurate Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global ESG Reporting Software Market- (By Component (Solutions, Services), By Deployment Type (On-premises, Cloud), By Organization Size (Large Enterprises, SMEs), By Vertical (BFSI, Government, Public Sector & Non-Profit, Retail)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global ESG Reporting Software Market is valued at US$ 0.71
Erdosteine Market is expected to Observe Considerable Growth Opportunities to 2031
Erdosteine Market is expected to Observe Considerable Growth Opportunities to 20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Erdosteine Market Size, Share & Trends Analysis Report By End User (Pharmaceuticals, Research Institutes, Contract Manufacturing Organizations), Application (Bronchitis, Chronic Obstructive Pulmonary Disease, Nasopharyngitis), Region, Market Outlook And Industry Analysis 2031" The global erdosteine market is estimated to reach over USD 301.61 Mn by 2031, exhibiting a CAGR of 8.45% during the forecast period. Get Free Access
Prepreg Market Current Scenario with Future Trends Analysis to 2031
Prepreg Market Current Scenario with Future Trends Analysis to 2031
"Prepreg Market" in terms of revenue was estimated to be worth $9.55 billion in 2023 and is poised to reach $25.67 billion by 2031, growing at a CAGR of 13.36% from 2024 to 2031 according to a new report by InsightAce Analytic. Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1611 Latest Drivers Restraint and Opportunities Market Snapshot: Key factors influencing the global prepreg market are: • Acceleration of the Market for

All 5 Releases


More Releases for Disease

Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and